EDMONTON, Canada, June 3 /PRNewswire/ -- Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive drug, voclosporin, on Wednesday, June 4th at 9:00 a.m. ET/7:00 a.m. MT.
As previously announced, the final Phase 2b kidney transplant trial (PROMISE) results will be presented during an oral presentation by Dr. Osama Gaber, Director of Transplantation, Vice-Chair for Administration and Faculty Affairs, Department of Surgery, The Methodist Hospital, Cornell University in New York at the 2008 American Transplant Congress in Toronto, Ontario. Dr. Gaber, as one of the principal investigators in the PROMISE trial, will present detailed data including the primary endpoint as determined by biopsy proven acute rejection and relevant safety data. Dr. Gaber's presentation is scheduled to take place on Tuesday, June 3 at 4:50 p.m. ET.
All interested parties will be able to access the live event (listen only mode) through the Company's corporate web site at http://www.isotechnika.com and access the replay at +1-416-640-1917 or +1-877-289-8525 using the pass code, 21273673.
About Isotechnika Inc. ----------------------
Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential will exceed CAD$4 billion annually in sales for calcineurin inhibitors such as voclosporin by 2010.
Voclosporin is a next generation calcineurin inhibitor, which recently completed a Phase 2b North American trial for the prevention of kidney rejection following transplantation. An extension to the Phase 2b trial and a combined Phase 3 European/Canadian trial for the treatment of moderate to severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently conducting three separate Phase 2/3 pivotal trials investigating voclosporin (referred to as LX211 by Lux) for the treatment of uveitis. Voclosporin has been approved to enter First-in-Man trials as the drug utilized in the CINATRA(TM) Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation.
Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at http://www.isotechnika.com.
Forward-Looking Statements --------------------------
This press release may contain forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Forward-looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, competition, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of the Company's Annual Information Form. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements.
For further information: Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661, Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com
For further information: Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661, Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com
Comments